Recall: Lidocaine Identified in Dexmedetomidine Vials
Administration of the recalled product to a patient with lidocaine allergy could potentially result in anaphylaxis if trace amounts of lidocaine are present.
Anesthetics
Type of Anesthesia Not Linked to Dementia Risk in Older Adults
Dementia risk did not differ by general, regional anesthesia in seniors undergoing elective surgery.
CNS-Active Meds Often Prescribed for Older Adults With Dementia
Overall, Rx filled for antidepressants in 49.8 percent, opioids in 29.8 percent, anxiolytics in 26.8 percent
FDA: Drug “In-Use Time” May Be Extended in Certain Cases
has provided guidance to healthcare facilities and providers looking to use certain drugs beyond their labeled “in-use times” due to supply issues related to the coronavirus disease 2019 (COVID-19) pandemic.
Fresenius Kabi Recalls Dexmedetomidine Over Possible Lidocaine Cross-Contamination
Fresenius Kabi announced the voluntary recall of 2 lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200mcg/50mL, 50mL fill in a 50mL vial due to the possibility of cross-contamination with lidocaine.
FDA Approves Byfavo for Induction and Maintenance of Procedural Sedation
The FDA has approved Byfavo™ (remimazolam; Acacia Pharma) for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
Propoven 2% Now Available for COVID-19 Patients Requiring Mechanical Ventilation
The FDA recently issued an Emergency Use Authorization for the use of Propoven 2% Emulsion as a result of the continued shortage of propofol which is needed for ventilating COVID-19 patients.
MPR Weekly Dose Podcast Episode 37
This week on the pod we look at results from a COVID-19 prevention trial of hydroxychloroquine; A vaccine arrival date prediction by Dr Fauci; A FDA notification regarding vial caps; A look into prescription patterns during COVID-19; And an antibody treatment trial begins.
FDA: Vial Caps of Two Neuromuscular Blocking Agents May Not Have Warning Statement
The FDA is notifying healthcare professionals regarding the temporary absence of the “paralyzing agent” warning statement on vial caps of vecuronium bromide for injection
FDA Issues EUA for Critical Med Needed for Ventilating COVID-19 Patients
The FDA has issued an Emergency Use Authorization to allow for the use of Propoven 2% (propofol 20mg/mL) Emulsion 100mL (Fresenius Kabi) to maintain sedation via continuous infusion in patients who require mechanical ventilation in an ICU setting during the COVID-19 pandemic.
